|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.65 / 5.05|
During another busy week, we rang the register and exited our position in Amplify, trimmed another name twice and scaled into a recent addition.
Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.
We bought into some tech names last week as a rotation occurred in the sector.
For the second week in a row, we initiated a new position, this time in a security tech name.
We initiated a new position for the portfolio during the shortened holiday trading week.
We exited three biotech/pharma positions and added to two other holdings during a busy week for the portfolio.
We exited two positions today following a tough week for small-cap stocks.
Earnings analysis on four stocks -- and we are increasing our ACRX position on this weakness.
Last week, we increased our holdings in one position and added 2 Bullpen names.
We used price declines to scale into several holdings as small-caps underperformed the overall market.
Keep a close eye on this one, and establish a stop-loss order at or around $9.50.
This week brings earnings from 5 portfolio holdings as the market continues to shrug off potential negatives.
We have to purchase some AcelRx Pharmaceuticals to take advantage of these prices.
We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.
We'll sell some AcelRx Pharmaceuticals and buy more Hudson Technologies.
We added to one name during a stellar week for the majority of the portfolio.
We took a healthy profit trimming one name and added to three other positions last week.
In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.50/share. That's a 182.05% rise, or $3.55 per share from the 52-week low of $1.95 set back on 06/12/2017.
We'll take the money and run by selling one-third of our stake in AcelRx Pharmaceuticals.
We added a digital security name to the Bullpen during a mixed week for the portfolio.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
We initiated 2 new positions and jettisoned another over the last week.
We remain cautious during this historically volatile month for the market.
We scaled into one position during a week dominated by Hurricane Harvey and its aftermath.
We initiated 2 small positions last week as the market moved higher.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.